January opens with a clear-eyed look at where the FDA stands one year into the new administration, and what that reality means for biopharma communicators right now. This theme focuses squarely on the FDA, examining how leadership shifts, policy direction, and internal dynamics are influencing approvals, enforcement, and expectations. We’re exploring the communications implications that often emerge before formal guidance, from increased scrutiny to evolving signals in how decisions are framed and explained. The goal is practical understanding: how the FDA is operating today, what feels unsettled or in motion, and how communicators can stay current, credible, and prepared as the year unfolds.